ACRS
Aclaris Therapeutics, Inc.
Medical - Diagnostics & Research
Market Cap$586M
5Y Perf.-78.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ACRS vs DAWN
Revenue, margins, valuation, and 5-year total return — side by side.
DAWN
Day One Biopharmaceuticals, Inc.
Biotechnology
Market Cap$2.22B
5Y Perf.-9.5%
ACRS vs DAWN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ACRS | DAWN |
|---|---|---|
| Industry | Medical - Diagnostics & Research | Biotechnology |
| Market Cap | $586M | $2.22B |
| Revenue (TTM) | $8M | $158M |
| Net Income (TTM) | $-65M | $-107M |
| Gross Margin | 73.3% | 89.1% |
| Operating Margin | -9.8% | -80.8% |
| Total Debt | $0.00 | $3M |
| Cash & Equiv. | $20M | $197M |
ACRS vs DAWN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ACRS
DAWN
| Stock | May 21 | May 26 | Return |
|---|---|---|---|
| Aclaris Therapeutic… (ACRS) | 100 | 21.9 | -78.1% |
| Day One Biopharmace… (DAWN) | 100 | 90.5 | -9.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ACRS vs DAWN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: DAWN leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Aclaris Therapeutics, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
ACRS
Aclaris Therapeutics, Inc.
The Income Pick
ACRS is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.30
- Lower volatility, beta 0.30, current ratio 5.28x
- Beta 0.30, current ratio 5.28x
Best for: income & stability and sleep-well-at-night
DAWN
Day One Biopharmaceuticals, Inc.
The Growth Play
DAWN carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 20.6%, EPS growth -2.0%
- -8.4% 10Y total return vs ACRS's -76.3%
- 20.6% revenue growth vs ACRS's -58.2%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | DAWN | 20.6% revenue growth vs ACRS's -58.2% |
| Quality / Margins | DAWN | -67.8% margin vs ACRS's -8.3% |
| Stability / Safety | ACRS | Beta 0.30 vs DAWN's 0.35 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ACRS | +288.8% vs DAWN's +241.7% |
| Efficiency (ROA) | DAWN | -20.7% ROA vs ACRS's -40.5%, ROIC -30.5% vs -53.5% |
ACRS vs DAWN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
ACRS vs DAWN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDAWNLAGGINGACRS
ACRSAclaris Therapeutics,…
0leads
DAWNDay One Biopharmaceut…
4leads
6 Total Categories
CATEGORYLEADERvs ACRSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DAWN5/6
Valuation MetricsMultiples, price ratios, and targets
DAWN3/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
DAWN6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
DAWN5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DAWN leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
DAWN is the larger business by revenue, generating $158M annually — 20.2x ACRS's $8M. Profitability is closely matched — net margins range from -67.8% (DAWN) to -8.3% (ACRS). On growth, DAWN holds the edge at +83.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ACRSAclaris Therapeut… | DAWNDay One Biopharma… |
|---|---|---|
| RevenueTrailing 12 months | $8M | $158M |
| EBITDAEarnings before interest/tax | -$76M | -$124M |
| Net IncomeAfter-tax profit | -$65M | -$107M |
| Free Cash FlowCash after capex | -$47M | -$108M |
| Gross MarginGross profit ÷ Revenue | +73.3% | +89.1% |
| Operating MarginEBIT ÷ Revenue | -9.8% | -80.8% |
| Net MarginNet income ÷ Revenue | -8.3% | -67.8% |
| FCF MarginFCF ÷ Revenue | -6.0% | -68.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -85.9% | +83.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +84.2% | +70.0% |
DAWN leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
DAWN leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
| Metric | ACRSAclaris Therapeut… | DAWNDay One Biopharma… |
|---|---|---|
| Market CapShares × price | $586M | $2.2B |
| Enterprise ValueMkt cap + debt − cash | $566M | $2.0B |
| Trailing P/EPrice ÷ TTM EPS | -9.17x | -20.70x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 74.83x | 14.06x |
| Price / BookPrice ÷ Book value/share | 5.78x | 5.05x |
| Price / FCFMarket cap ÷ FCF | — | — |
DAWN leads this category, winning 3 of 3 comparable metrics.
Profitability & Efficiency
DAWN leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
DAWN delivers a -23.4% return on equity — every $100 of shareholder capital generates $-23 in annual profit, vs $-63 for ACRS. On the Piotroski fundamental quality scale (0–9), DAWN scores 4/9 vs ACRS's 3/9, reflecting mixed financial health.
| Metric | ACRSAclaris Therapeut… | DAWNDay One Biopharma… |
|---|---|---|
| ROE (TTM)Return on equity | -63.0% | -23.4% |
| ROA (TTM)Return on assets | -40.5% | -20.7% |
| ROICReturn on invested capital | -53.5% | -30.5% |
| ROCEReturn on capital employed | -47.7% | -26.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | — | 0.01x |
| Net DebtTotal debt minus cash | -$20M | -$194M |
| Cash & Equiv.Liquid assets | $20M | $197M |
| Total DebtShort + long-term debt | $0 | $3M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
DAWN leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
DAWN leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DAWN five years ago would be worth $9,162 today (with dividends reinvested), compared to $2,118 for ACRS. Over the past 12 months, ACRS leads with a +288.8% total return vs DAWN's +241.7%. The 3-year compound annual growth rate (CAGR) favors DAWN at 18.2% vs ACRS's -16.7% — a key indicator of consistent wealth creation.
| Metric | ACRSAclaris Therapeut… | DAWNDay One Biopharma… |
|---|---|---|
| YTD ReturnYear-to-date | +68.8% | +143.3% |
| 1-Year ReturnPast 12 months | +288.8% | +241.7% |
| 3-Year ReturnCumulative with dividends | -42.1% | +65.1% |
| 5-Year ReturnCumulative with dividends | -78.8% | -8.4% |
| 10-Year ReturnCumulative with dividends | -76.3% | -8.4% |
| CAGR (3Y)Annualised 3-year return | -16.7% | +18.2% |
DAWN leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ACRS and DAWN each lead in 1 of 2 comparable metrics.
Risk & Volatility
ACRS is the less volatile stock with a 0.30 beta — it tends to amplify market swings less than DAWN's 0.35 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | ACRSAclaris Therapeut… | DAWNDay One Biopharma… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.30x | 0.35x |
| 52-Week HighHighest price in past year | $4.89 | $21.53 |
| 52-Week LowLowest price in past year | $1.16 | $5.64 |
| % of 52W HighCurrent price vs 52-week peak | +99.4% | +100.0% |
| RSI (14)Momentum oscillator 0–100 | 66.0 | 80.3 |
| Avg Volume (50D)Average daily shares traded | 1.9M | 4.9M |
Evenly matched — ACRS and DAWN each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ACRS as "Buy" and DAWN as "Buy". Consensus price targets imply 105.8% upside for ACRS (target: $10) vs 10.3% for DAWN (target: $24).
| Metric | ACRSAclaris Therapeut… | DAWNDay One Biopharma… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $10.00 | $23.75 |
| # AnalystsCovering analysts | 16 | 12 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
DAWN leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallDay One Biopharmaceuticals,… (DAWN)Leads 4 of 6 categories
Loading custom metrics...
ACRS vs DAWN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ACRS or DAWN a better buy right now?
For growth investors, Day One Biopharmaceuticals, Inc.
(DAWN) is the stronger pick with 20. 6% revenue growth year-over-year, versus -58. 2% for Aclaris Therapeutics, Inc. (ACRS). Analysts rate Aclaris Therapeutics, Inc. (ACRS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ACRS or DAWN?
Over the past 5 years, Day One Biopharmaceuticals, Inc.
(DAWN) delivered a total return of -8. 4%, compared to -78. 8% for Aclaris Therapeutics, Inc. (ACRS). Over 10 years, the gap is even starker: DAWN returned -8. 4% versus ACRS's -76. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ACRS or DAWN?
By beta (market sensitivity over 5 years), Aclaris Therapeutics, Inc.
(ACRS) is the lower-risk stock at 0. 30β versus Day One Biopharmaceuticals, Inc. 's 0. 35β — meaning DAWN is approximately 17% more volatile than ACRS relative to the S&P 500.
04Which is growing faster — ACRS or DAWN?
By revenue growth (latest reported year), Day One Biopharmaceuticals, Inc.
(DAWN) is pulling ahead at 20. 6% versus -58. 2% for Aclaris Therapeutics, Inc. (ACRS). On earnings-per-share growth, the picture is similar: Aclaris Therapeutics, Inc. grew EPS 69. 0% year-over-year, compared to -2. 0% for Day One Biopharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ACRS or DAWN?
Day One Biopharmaceuticals, Inc.
(DAWN) is the more profitable company, earning -67. 8% net margin versus -829. 6% for Aclaris Therapeutics, Inc. — meaning it keeps -67. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DAWN leads at -80. 8% versus -975. 9% for ACRS. At the gross margin level — before operating expenses — DAWN leads at 89. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ACRS or DAWN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ACRS or DAWN better for a retirement portfolio?
For long-horizon retirement investors, Aclaris Therapeutics, Inc.
(ACRS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 30)). Both have compounded well over 10 years (ACRS: -76. 3%, DAWN: -8. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ACRS and DAWN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ACRS is a small-cap quality compounder stock; DAWN is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(ACRS: -85.9% · DAWN: 83.9%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.